Overcoming the immunosuppressive environment of neuroblastoma

Neuroblastoma is a solid neuroendocrine tumor, which arises mostly in very young children. The addition of the immunotherapy Dinutuximab has led to a small increase in the survival rate of children with the diagnosis high-risk neuroblastoma. This, together with promising results of immunotherapies in adult solid cancers, make neuroblastoma a good candidate for immunotherapies. This project will look into the immunosuppressive environment of the neuroblastoma tumors and how we can overcome this.

Contact 
Josephine Strijker